TFRC and triple-negative breast carcinoma: Pandolfi et al. (2017) analyzed the effect of nano-drug H-ferritin-curcumin on triple-negative breast cancer and found that the nanomedicine can enhance the cytotoxic effect of doxorubicin by interfering with the activity of multidrug resistance transporters; block MDA-MB-231 in G0/G1 phase, and accumulate MDA-MB-468 in G2/M phase. Inoue et al. (2021) demonstrated that doxorubicin-loaded ferritin heavy chain could be taken up and induce apoptosis of cancer cells overexpressing TfR1.